LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
FAA Unveils Flight Plan 2026 to Strengthen Aviation Safety and Workforce Development 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Republicans Raise National Security Concerns Over Intel’s Testing of China-Linked Chipmaking Tools 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
REHOVOT, Israel, Nov. 02, 2016 -- Evogene Ltd. (NYSE:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the third quarter of 2016 on Monday, November 21, 2016.
On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-668-9141 toll free from the United States, or +972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.
A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-254-7270 toll free from the United States, or +972-3-925-5937 internationally. The replay will be accessible through November 23, 2016, and an archive of the webcast will be available on the Company’s website through December 2, 2016.
About Evogene Ltd.:
Evogene (NYSE:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at [email protected].
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Karen Mazor, Director Investor Relations E: [email protected] T: +972 54 228 2039
